Levan-based mrna delivery system for enhanced gene therapy
Levan-based nanoparticles offer a novel, non-viral gene delivery system for mRNA therapeutics, addressing challenges like immunogenicity and toxicity. With biocompatibility and biodegradability, this system is cost-effective, scalable, and suitable for cancer and genetic disorder treatments.
Overview
The levan-based mRNA delivery system represents a breakthrough in gene therapy, providing a non-viral vector alternative for efficient and safe gene delivery. This system leverages the unique properties of levan nanoparticles, which are biocompatible, biodegradable, and capable of self-assembly. Unlike traditional lipid nanoparticles, levan offers additional antioxidant, anti-inflammatory, and antitumor benefits, enhancing therapeutic outcomes. This innovation is particularly suited for applications in cancer treatment, genetic disorder management, and combating infectious diseases, offering a scalable and cost-effective solution.
Technical specifications
Key features:
- Biocompatibility and Biodegradability: Ensures minimal immune response and safe breakdown in the body.
- Self-Assembly and Controlled Release: Levan nanoparticles protect mRNA from degradation and allow for precise gene delivery.
- Functionalization Capabilities: Chemical versatility supports enhanced drug loading and targeted delivery.
- Flash Nano-Complexation Technique: Enables the synthesis of stable nanoparticles without toxic solvents, optimizing encapsulation efficiency and cellular uptake.
- Antioxidant, Anti-Inflammatory, and Antitumor Properties: Provides additional therapeutic benefits beyond gene delivery.
Technology readiness level
Currently at Technology Readiness Level 2, this system is in the early stages of development. Initial bench-scale production and purification processes are being established, with ongoing characterization and optimization of the levan-based mRNA nanoparticles. Comprehensive in vitro and in vivo testing is planned to evaluate safety, efficacy, and potential for clinical application.
About BIOARTHA LABS PRIVATE LIMITED
BioArtha Labs Private Limited is a biotechnology company based in Bengaluru, India, that specializes in research services and the manufacturing of high-quality life science products. The company develops solutions for molecular biology, protein biology, chromatography, and in-vitro diagnostics (IVD). Its technical capabilities include recombinant protein production, custom antibody development, strain engineering, synthetic biology, and immunoassay development. Operating from ISO 13485:2016 certified facilities, BioArtha Labs provides standardized and customized products designed to support scientific research and industrial applications worldwide.
The company serves the global scientific community and healthcare industry by providing reliable, performance-driven tools and services that accelerate research, development, and production workflows. By maintaining state-of-the-art facilities and implementing stringent quality control, BioArtha Labs acts as a strategic partner to researchers and organizations requiring high-quality reagents and technical support. Since its incorporation in 2021, the company has focused on advancing scientific discovery and improving health outcomes through innovative biotech solutions and customer-centric service delivery.
delivered to your inbox.